Skullcap Safety: Germander Adulteration and Liver Injury

Table of Contents

1. Why This Is the Page That Matters
2. What Germander Is
3. How Germander Damages the Liver
4. The French Cluster and the Withdrawal
5. How Germander Ended Up in Skullcap
6. The Skullcap-Labelled Case Reports
7. What the Attribution Does and Does Not Prove
8. Chinese Skullcap's Separate Liver Signal
9. How Plant Identity Is Actually Verified
10. What Labels and Testing Can Show When Buying Skullcap
11. Recognising Liver Injury
12. Who the Research Raises Concerns For
13. The Broader Lesson
14. Key Research Papers
15. Connections
16. Featured Videos

Why This Is the Page That Matters

Most of what is written about skullcap concerns benefits with modest evidence behind them: a small randomized trial or two for anxiety, tradition for sleep, and a large volume of laboratory work that belongs to a different species. The potential upside of taking the herb is therefore real but small. The 2014 crossover trial gave 43 healthy volunteers, most of them mildly anxious or less, 350 mg three times daily or placebo, each for two weeks. The anxiety score did not differ significantly from placebo (p = 0.191), while total mood disturbance fell significantly on skullcap and not on placebo; the authors name a carryover effect and generally low anxiety scores as limits of the study (PubMed PMID: 23878109).

The adulteration story is different in kind. Severe liver injury is a low-probability event, but it is a high-consequence one — germander hepatitis in the French cluster included cases that progressed to serious liver failure. When an intervention offers a modest benefit and carries a small chance of a severe harm, the harm side weighs heavily, and the step that addresses it — an authenticated product — costs little. That asymmetry is why this page exists and why it is placed alongside the benefits rather than buried in a footnote.

What Germander Is

Evidence tier: botany and regulatory history.

Germander is the common name of Teucrium, a genus of well over two hundred species distributed mainly around the Mediterranean and across western Asia. Three matter here:

• Teucrium chamaedrys, wall germander — the species at the centre of the French hepatitis cluster. A low, woody, small-leaved plant traditionally used as a bitter tonic and, more recently, marketed in capsules and infusions as a slimming aid.
• Teucrium canadense, American germander — named with T. chamaedrys in the published adulteration analyses, which state that skullcap “has occasionally been adulterated with Teucrium canadense or T. chamaedrys” (PubMed PMID: 19402188). This is the species a North American product could contain.
• Teucrium polium, felty germander — widely used in traditional medicine across the Middle East and North Africa, and independently implicated in liver-injury reports from that region (PubMed search). The problem is not confined to one species.

The detail that makes the substitution possible is taxonomic proximity. Teucrium and Scutellaria are both members of the mint family, Lamiaceae. Both are low herbaceous plants with square stems, opposite paired leaves, small toothed leaf margins and small two-lipped flowers. Neither has a strong distinguishing aroma once dried. Reduced to a bag of crumbled grey-green leaf, they are not easy to tell apart by eye — and reduced to a powder inside a capsule, they are impossible.

How Germander Damages the Liver

Evidence tier: mechanistic animal and cell studies, unusually well worked out for a herbal toxin.

Germander is not vaguely “bad for the liver.” Its toxicology has been characterised in a way that few herbal safety questions ever are, and the mechanism is worth understanding because it explains why the injury can be severe and why some people are affected while others are not.

The culprits are a class of compounds called neoclerodane diterpenes, of which teucrin A is the best studied. These molecules carry a furan ring, and a furan ring is a classic structural alert in toxicology: it is chemically unremarkable until an enzyme oxidises it, at which point it becomes a highly reactive electrophile. The sequence runs roughly as follows:

1. Bioactivation. Cytochrome P450 enzymes in the liver — principally the CYP3A subfamily — oxidise the furan ring of teucrin A and its relatives to a reactive epoxide-type metabolite. The parent compound is comparatively harmless; the liver creates the poison in the act of trying to clear it.
2. Glutathione depletion. Reactive metabolites are mopped up by glutathione. Sustained exposure exhausts that defence, and once glutathione falls the reactive species reach their targets.
3. Protein adduct formation. The metabolites bind covalently to cellular proteins, including thiol groups on cytoskeletal proteins. Rat-hepatocyte work described loss of cytoskeleton-associated protein thiols and formation of membrane blebs — a visible sign that the cell's structural scaffolding is failing (PubMed PMID: 8707265).
4. Cell death. The result in animal models is apoptosis and necrosis of hepatocytes, corresponding clinically to a hepatocellular pattern of injury with markedly raised transaminases.
5. Possible immune involvement. Protein adducts can also act as neo-antigens, and some germander cases showed features suggesting an immune component, which would help explain why injury recurred rapidly on re-exposure in some patients.

The two foundational animal papers are Hepatotoxicity of germander (Teucrium chamaedrys L.) and one of its constituent neoclerodane diterpenes teucrin A in the mouse (Chemical Research in Toxicology, 1994; PubMed PMID: 7696542) and Hepatotoxicity of germander in mice (Gastroenterology, 1994; PubMed PMID: 8299912).

In plain terms, the mouse experiments tested each step. Blocking CYP3A with the drug troleandomycin prevented the injury, while dexamethasone and clotrimazole, which switch CYP3A up, made it worse; lowering glutathione markedly worsened it (PubMed PMID: 8299912). When the furan ring of teucrin A was chemically reduced, the altered molecule no longer harmed the liver, which is strong evidence that oxidising that ring starts the damage (PubMed PMID: 7696542).

Three consequences are drawn from this mechanism. First, dose and duration are expected to matter in animals, because the injury depends on outrunning glutathione (in mice, 1.25 g/kg of germander tea concentrate produced liver-cell necrosis at 24 hours). The human record differs: in the 26 French cases there was “no relationship with the daily intake and the duration of treatment” (PubMed PMID: 1493896). Second, anything that induces CYP3A or depletes glutathione could plausibly worsen it — which includes alcohol, fasting, and a number of medications. Third, susceptibility varies between individuals, which is why a cluster of cases can emerge from a product that thousands of other people took without apparent harm. That last point is the reason absence of reported harm is weak evidence of safety.

The French Cluster and the Withdrawal

Evidence tier: clinical case series and regulatory action.

In the late 1980s germander was being sold in France in capsules and teas, largely as a slimming aid — a use with no evidence behind it, taken by otherwise healthy people, often for weeks or months. Hepatologists began seeing hepatitis in patients whose only common exposure was this product. The pivotal report, Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity, appeared in Annals of Internal Medicine in 1992 (PubMed PMID: 1605427).

That report covered 7 patients with no other cause of liver injury. Jaundice and a marked rise in aminotransferases (liver enzymes) appeared 3 to 18 weeks after starting germander; biopsy showed liver-cell death in 3; jaundice was gone within 8 weeks of stopping and recovery was complete in 1.5 to 6 months; and hepatitis promptly returned in the 3 who took germander again (PubMed PMID: 1605427).

The wider French pharmacovigilance record held 26 people with acute hepatitis. Onset came within 9 weeks, recovery came 1.5 to 6 months after stopping, and in 12 cases taking germander again brought the hepatitis back. The French Ministry of Health then prohibited all germander-containing medicinal products (PubMed PMID: 1493896).

The clinical picture reported in that literature had several features that made causation persuasive rather than merely suspected:

• A consistent hepatocellular pattern — jaundice with markedly elevated transaminases, appearing after weeks to months of use.
• Improvement on stopping the product in most patients, the single most informative observation in drug-induced liver injury.
• Recurrence, sometimes faster and more severe, on re-exposure in patients who resumed the product — the closest thing to a natural experiment that clinical toxicology gets, and strong evidence of causation.
• Serious outcomes in a minority, including progression toward liver failure, which is what moved this from a curiosity to a regulatory matter.
• Absence of an alternative explanation after investigation for viral hepatitis, autoimmune disease and alcohol.

French authorities withdrew germander from sale in 1992. The episode became a standard teaching case in hepatology for herbal hepatotoxicity, and it is why germander appears in reference works on drug and herb-induced liver injury such as LiverTox, hosted on the NCBI Bookshelf. Reviews of hepatotoxic slimming products and other herbal liver toxins routinely include it (PubMed search).

How Germander Ended Up in Skullcap

Evidence tier: quality-control analyses and pharmacopoeial monographs.

Substitution of one dried herb for another does not require a conspiracy. Several ordinary pressures produce it:

1. Morphological similarity. As described above, dried Teucrium and dried Scutellaria leaf are genuinely hard to distinguish, and both lack a diagnostic smell.
2. Wild collection and long supply chains. Skullcap has historically been wild-harvested. Material can pass through collectors, aggregators, brokers, exporters and repackagers before reaching a manufacturer, and identity claims are inherited at each step rather than re-tested.
3. Price and scarcity. When authentic material is expensive or in short supply, a cheaper look-alike becomes attractive somewhere along that chain.
4. Common names as a failure point. Herb trading has often used common names, which are ambiguous across regions and languages. A binomial travels; a folk name does not.
5. Powdering and encapsulation destroy the evidence. Once material is milled, the botanical features a trained eye would use are gone. Capsules and multi-herb blends are therefore where adulteration is least detectable.

This is not speculative reconstruction. Identity and adulteration are treated as central concerns in the American Herbal Pharmacopoeia monograph Skullcap Scutellaria lateriflora L.: an American nervine (Journal of Herbal Medicine, 2012; doi:10.1016/j.hermed.2012.06.004) and examined directly in Identity issues surrounding American skullcap (Scutellaria lateriflora) and an optimised high performance liquid chromatography method to authenticate commercially available products (Journal of Herbal Medicine, 2013; doi:10.1016/j.hermed.2013.02.001). Beyond germander, the same literature notes substitution with other Scutellaria species such as S. galericulata — less dangerous, but still not the herb the label claims.

The Skullcap-Labelled Case Reports

Evidence tier: clinical case reports, with attribution that is reasoned rather than proven.

The reports that gave skullcap its reputation date largely to the late 1980s and after. Hepatotoxicity of herbal remedies in the BMJ in 1989 (PubMed PMID: 2513032) described liver injury in patients taking herbal products that included skullcap, commonly in combination with valerian. Additional scattered reports followed. Skullcap consequently appears on lists of herbs associated with hepatotoxicity, and it is fair to say the association exists in the literature.

What that association can and cannot establish deserves care, because case reports of multi-ingredient herbal products are among the weakest forms of causal evidence available:

• Multiple ingredients. When a product contains several herbs, a case report implicates the product, not a component. Attribution to skullcap specifically was an inference.
• The material was rarely analysed. In most reports the actual product was not chemically or botanically tested, so nobody knows what the patient took. Where analysis was possible, germander was found in some skullcap-labelled material — which is the origin of the reattribution.
• Clinical presentation fits germander. The pattern in the skullcap-labelled cases resembled the well-characterised germander picture, which strengthens the substitution hypothesis without proving it in any individual case.
• No mechanism has been established for skullcap itself. Unlike germander's furan-diterpene bioactivation, there is no known hepatotoxic constituent or mechanism identified in S. lateriflora. Absence of a known mechanism is not proof of safety, but it is a meaningful asymmetry between the two plants.

Case reports continue. A 2023 report describes a previously healthy woman with sudden jaundice after what she called “Skullcap mushroom supplements”: a first biopsy showed drug-induced liver injury, a second confirmed autoimmune hepatitis, and her liver enzymes improved after she stopped. The authors attribute it to North American skullcap and call it the first documented instance of this association; the report describes no laboratory test of the product itself (PubMed PMID: 38223420). A 2024 editorial discusses that report (PubMed PMID: 38495279). Because the plant in the capsules is not established, this adds to the “not proven” side and does not settle the question.

What the Attribution Does and Does Not Prove

This section is the crux, because the germander explanation is routinely deployed as reassurance and that use of it is not honest.

What it legitimately supports:

• Correctly identified S. lateriflora aerial parts have no established hepatotoxic constituent and no demonstrated mechanism of liver injury.
• The old “skullcap damages the liver” claim, stated flatly, is probably wrong as a statement about the plant.
• A substantial part of the historical risk was a supply-chain failure and is therefore addressable rather than intrinsic.

What it does not support:

• It does not clear any particular bottle. The exonerating argument applies to the plant, and only to products that actually contain the plant. A label alone does not verify it.
• It does not prove skullcap has never caused liver injury. Most reported cases were never analysed, so some may genuinely have involved authentic material. The correct statement is that skullcap-labelled products have been associated with liver injury and that germander substitution is the leading explanation — not that skullcap is definitively innocent.
• It does not mean the risk is historical. Botanical adulteration remains an active concern across the supplement market, which is why nonprofit botanical organisations run ongoing adulterants-prevention programmes. The problem is monitored because it has not gone away.
• It does not make identity optional. If the safety of a product rests on it containing what it says, then verification is the safety measure, not a nicety.

The record therefore supports neither the old alarm nor the modern brush-off. What it shows is that this plant is probably benign, that the marketplace is the demonstrated risk, and that testing of identity is what addresses that risk.

Chinese Skullcap's Separate Liver Signal

Evidence tier: clinical case series and clinical review.

A reader who has absorbed the germander story sometimes concludes that all skullcap liver concerns are impostor problems. They are not, and the other species has a distinct issue where the implicated ingredient is the herb itself.

Chinese skullcap root (Scutellaria baicalensis) and its flavone baicalin appear in the herbal hepatotoxicity literature. The clearest example is the flavocoxid preparations, marketed for osteoarthritis and combining baicalin from S. baicalensis with catechins from another plant; a case series of acute liver injury attributed to that product was published in Annals of Internal Medicine in 2012 (PubMed PMID: 22711078). Among 877 people in a United States liver-injury study, 4 had injury suspected to come from the product. All were women aged 57 to 68, and it began 1 to 3 months after they started. Liver tests returned to normal 3 to 12 weeks after stopping, and all recovered without liver failure. The wider setting appears in Liver injury from herbal and dietary supplements (Hepatology, 2017; PubMed PMID: 27677775), the report of a research symposium drawing on prospective registry data: herbal and dietary supplements made up 20% of United States liver-toxicity cases in research data, mostly multi-ingredient products whose responsible ingredient is usually unknown. That report does not name Scutellaria.

Three points keep this in proportion. The signal involves concentrated modern preparations more than traditional formula-level doses; the herb is consumed on an enormous scale in East Asia, so the absolute risk per user must be low; and, as noted on the baicalin page, baicalin has paradoxically been reported to protect rodent livers in model systems — a reminder that animal protection data cannot be used to reassure anyone about a human safety signal. The practical upshot is simply that “skullcap” on a label may be either species, and both have a liver question, for different reasons.

How Plant Identity Is Actually Verified

What the verification looks like shows whether a manufacturer's claim means anything.

1. Macroscopic and organoleptic examination. A trained analyst inspects whole or coarsely cut material against a monograph description — leaf shape and margin, stem cross-section, flower structure, colour, taste. Cheap and effective on whole herb, useless on powder.
2. Microscopy. Cellular features such as trichome type and epidermal patterning survive milling and can distinguish related genera. This is the classical pharmacognosy method and it is still valuable.
3. Chromatographic fingerprinting. Thin-layer chromatography or HPLC produces a pattern of constituent peaks compared against an authenticated reference. For this specific problem it is powerful, because the relevant marker is unambiguous: teucrin A and related neoclerodane diterpenes belong to germander and are not expected in genuine skullcap. A test that looks for the adulterant's marker rather than only for the target herb's markers is the stronger design. A published chromatography method used a different pair of germander markers, the phenylethanoids verbascoside and teucrioside: skullcap contained mainly flavonoids, and 5% Teucrium mixed with skullcap could be detected, or 1% with a more selective mass-spectrometry mode (PubMed PMID: 19402188). Near-infrared imaging also separates the raw plant materials without destroying them, though it measured added germander accurately only at levels of 40% or more (PubMed PMID: 25184892).
4. DNA barcoding. Sequencing standard marker regions identifies the species from which the material came, and works even on powder. It has limits — DNA degrades in highly processed extracts, and it identifies species without quantifying how much of each is present — so it complements rather than replaces chemistry.
5. Documented chain of custody. Records tying a finished batch back to a specific harvest, with certificates of analysis at each transfer. Unglamorous, and the thing that actually prevents substitution rather than merely detecting it.

Independent programmes exist because none of this happens by default: nonprofit botanical organisations run an adulterants prevention programme publishing bulletins on specific herbs, while independent standards and testing bodies operate supplement verification schemes. Such marks address identity, purity and manufacturing quality — not whether the herb works. In the United States, dietary supplements are not approved for safety or efficacy before sale; the U.S. Food and Drug Administration (FDA) acts largely after problems appear.

What Labels and Testing Can Show When Buying Skullcap

The points below follow from the record above, in rough order of importance:

1. The binomial and the plant part. “Scutellaria lateriflora, aerial parts” names the nervine; “Scutellaria baicalensis, root” names the Chinese herb. A label that says only “Skullcap” does not tell which plant is inside.
2. Whole or coarsely cut dried herb compared with powder and capsules. Visible plant material can be inspected and smelled; powder cannot. Powder and capsules are the conditions under which the historical substitution went unnoticed.
3. Makers who state that identity was tested, and who supply a certificate of analysis on request, give information a bare label does not. A company that cannot answer “how do you verify the species?” leaves that question open.
4. Third-party verification is a proxy for manufacturing discipline, and it says nothing about efficacy.
5. Multi-herb blends and “proprietary formulas.” Every extra botanical is another identity risk, and undisclosed amounts make both dose and interaction assessment impossible.
6. Weight-loss and “detox” products. Germander's own disaster happened in a slimming product, and that category has produced a disproportionate share of herbal liver injury generally.
7. Unlabelled bulk herb from unfamiliar sources. Loose-leaf material with no species name and no provenance is exactly the material that caused the problem.
8. The packaging. If something goes wrong, the batch number and the actual product are what allow a clinician or regulator to investigate.

Recognising Liver Injury

Herb-induced liver injury is uncommon, and it is also easy to miss early because the first symptoms are unremarkable. These are signs of liver injury that hospitals treat as urgent, and in the reported germander cases recovery followed stopping the product:

• Unusual, persistent fatigue — frequently the earliest and most easily dismissed sign.
• Loss of appetite, nausea, or vomiting.
• Discomfort or aching in the right upper abdomen.
• Dark, tea-coloured urine and pale or clay-coloured stools.
• Yellowing of the skin or the whites of the eyes (jaundice) — a clear signal of liver injury.
• Itching without a rash.
• Easy bruising, or confusion and drowsiness — features of advanced impairment and a medical emergency.

Two things help a clinician enormously: the suspected product having been stopped, and the actual bottle rather than a description of it. Diagnosis rests on blood tests: Liver Function Tests covers what alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin indicate, and Liver Disease the broader picture. Herb-induced liver injury is frequently missed because patients do not think of supplements as drugs, so a list of every supplement, not just the suspected one, is part of that history.

Who the Research Raises Concerns For

• Anyone with existing liver disease of any kind — hepatitis, cirrhosis, fatty liver disease, or unexplained abnormal liver tests. The margin for error is smaller and the expected upside is modest.
• People who have had a previous drug- or herb-induced liver injury.
• People taking medications with known liver toxicity or narrow safety margins — certain antibiotics, antifungals, antiepileptics, methotrexate, isoniazid, high-dose paracetamol, among others. These medicines add to the load on the liver.
• Heavy alcohol users. Alcohol induces cytochrome P450 2E1 (CYP2E1), stresses the liver and depletes glutathione, all of which point the wrong way.
• Pregnant and breastfeeding women. Insufficient safety data for either species.
• Children. There is little safety data, despite the traditional claim of gentleness.
• People facing surgery. Anaesthetists ask about calming herbs, and surgical practice commonly has them stopped well in advance.
• People who cannot confirm what species the product contains. That is not a fussy preference — on the evidence above, it is the whole safety question.

The Broader Lesson

The germander–skullcap episode is a small story that carries a large and uncomfortable general point: a herb can be gentle and still harm you, if what is in the container is not what the label says. Efficacy and safety are both properties of an actual product, not of a plant name. In a market where premarket verification is not required, the label is a claim rather than a guarantee.

Four transferable points:

1. Botanical name and plant part. Common names are ambiguous and ambiguity is where substitution lives.
2. Processing is a loss of information. Whole herb can be checked; extract powder in a capsule must be trusted.
3. Benefit against harm. Where the benefit is modest and human evidence is thin, even a small chance of severe harm weighs heavily.
4. Clinicians and supplements. They cannot connect an unexplained hepatitis to a herbal tea nobody mentioned.

The point of all this is not to frighten anyone away from a mild traditional tea. It is that the one genuinely important thing to know about skullcap is a supply-chain fact rather than a pharmacological one — and that is unusual enough to be worth a page of its own.

Key Research Papers

Each named paper links to its fixed PubMed record or DOI, with an explicit evidence tier; the topic searches below the list cover the wider literature.

1. Larrey D, Vial T, Pauwels A, Castot A, Biour M, David M, Michel H. Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity. Annals of Internal Medicine. 1992;117(2):129-132. The pivotal French clinical series, including improvement on withdrawal and recurrence on re-exposure. Clinical case series. PubMed PMID: 1605427
2. Kouzi SA, McMurtry RJ, Nelson SD. Hepatotoxicity of germander (Teucrium chamaedrys L.) and one of its constituent neoclerodane diterpenes teucrin A in the mouse. Chemical Research in Toxicology. 1994;7(6):850-856. Identifies teucrin A as a hepatotoxic constituent. Animal toxicology. PubMed PMID: 7696542
3. Loeper J, Descatoire V, Letteron P, Moulis C, Degott C, Dansette P, Fau D, Pessayre D. Hepatotoxicity of germander in mice. Gastroenterology. 1994;106(2):464-472. Liver-cell necrosis in mice at 1.25 g/kg of germander tea concentrate, and the role of metabolic activation. Animal toxicology. PubMed PMID: 8299912
4. Lekehal M, Pessayre D, Lereau JM, Moulis C, Fouraste I, Fau D. Hepatotoxicity of the herbal medicine germander: metabolic activation of its furano diterpenoids by cytochrome P450 3A depletes cytoskeleton-associated protein thiols and forms plasma membrane blebs in rat hepatocytes. Hepatology. 1996;24(1):212-218. The cellular mechanism of injury. Cell and animal mechanism. PubMed PMID: 8707265
5. MacGregor FB, Abernethy VE, Dahabra S, Cobden I, Hayes PC. Hepatotoxicity of herbal remedies. BMJ. 1989;299(6708):1156-1157. Liver injury in patients taking skullcap-containing herbal products — the reports that created skullcap's reputation. Clinical case reports, multi-ingredient products. PubMed PMID: 2513032
6. Brock C, Whitehouse J, Tewfik I, Towell T. Identity issues surrounding American skullcap (Scutellaria lateriflora) and an optimised high performance liquid chromatography method to authenticate commercially available products. Journal of Herbal Medicine. 2013;3(2):57-64. Direct examination of substitution risk in commercial skullcap. Quality-control analysis. doi:10.1016/j.hermed.2013.02.001
7. Upton R, Dayu RH. Skullcap Scutellaria lateriflora L.: an American nervine. Journal of Herbal Medicine. 2012;2(3):76-96. The American Herbal Pharmacopoeia monograph, treating identity and authentication as central. Monograph review. doi:10.1016/j.hermed.2012.06.004
8. Chalasani N, Vuppalanchi R, Navarro V, Fontana R, Bonkovsky H, Barnhart H, Kleiner DE, Hoofnagle JH. Acute liver injury due to flavocoxid (Limbrel), a medical food for osteoarthritis: a case series. Annals of Internal Medicine. 2012;156(12):857-860. The Chinese-skullcap side of the liver story, where the implicated ingredient is the herb itself. Clinical case series. PubMed PMID: 22711078
9. Navarro VJ, Khan I, Björnsson E, Seeff LB, Serrano J, Hoofnagle JH. Liver injury from herbal and dietary supplements. Hepatology. 2017;65(1):363-373. Report of a research symposium; it does not name Scutellaria. Clinical review. PubMed PMID: 27677775
10. Castot A, Larrey D. [Hepatitis observed during a treatment with a drug or tea containing Wild Germander. Evaluation of 26 cases reported to the Regional Centers of Pharmacovigilance]. Gastroenterologie Clinique et Biologique. 1992;16(12):916-922. In French. Clinical case series. PubMed PMID: 1493896
11. Lin LZ, Harnly JM, Upton R. Comparison of the phenolic component profiles of skullcap (Scutellaria lateriflora) and germander (Teucrium canadense and T. chamaedrys), a potentially hepatotoxic adulterant. Phytochemical Analysis. 2009;20(4):298-306. Quality-control analysis. PubMed PMID: 19402188
12. Sandasi M, Vermaak I, Chen W, Viljoen AM. Skullcap and germander: preventing potential toxicity through the application of hyperspectral imaging and multivariate image analysis as a novel quality control method. Planta Medica. 2014;80(15):1329-1339. Quality-control analysis. PubMed PMID: 25184892
13. Thakral N, Konjeti VR, Salama FW. Drug induced autoimmune hepatitis: An unfortunate case of herbal toxicity from Skullcap supplement: A case report. World Journal of Hepatology. 2023;15(12):1333-1337. Clinical case report. PubMed PMID: 38223420
14. Soldera J. Insights into skullcap herb-induced liver injury. World Journal of Hepatology. 2024;16(2):120-122. Editorial. PubMed PMID: 38495279
15. Brock C, Whitehouse J, Tewfik I, Towell T. American Skullcap (Scutellaria lateriflora): a randomised, double-blind placebo-controlled crossover study of its effects on mood in healthy volunteers. Phytotherapy Research. 2014;28(5):692-698. Randomized crossover trial. PubMed PMID: 23878109

PubMed Topic Searches

1. Liver injury associated with Teucrium polium in traditional use across the Middle East and North Africa — evidence that the problem is a genus property, not one product. Clinical case reports. PubMed search
2. Reviews of hepatotoxic slimming aids and other herbal hepatotoxins, in which germander is a standard example. Clinical review literature. PubMed search
3. DNA barcoding and chromatographic authentication of herbal raw materials, including detection of substituted species in botanical supplements. Analytical methodology. PubMed search
4. Causality assessment in herb-induced liver injury — how clinicians decide whether a supplement caused a hepatitis, and why multi-ingredient products are so hard to adjudicate. Clinical methodology. PubMed search

External Resources

1. NCBI Bookshelf — hosts LiverTox, the NIH reference on drug and herbal liver injury, with entries for germander and for skullcap.
2. National Institute of Diabetes and Digestive and Kidney Diseases — liver disease information and the LiverTox programme.
3. NIH National Center for Complementary and Integrative Health — herb safety summaries.
4. U.S. Food and Drug Administration — supplement regulation and adverse-event reporting.
5. MedlinePlus — plain-language information on liver symptoms and tests.

Back to Table of Contents

Back to Table of Contents

Connections

• All Herbs
• Skullcap (main article)
• Skullcap Benefits Hub
• American vs Chinese Skullcap
• Skullcap for Anxiety and Sleep
• Baicalin and Chinese Skullcap Research
• Liver Disease
• Cirrhosis
• Autoimmune Hepatitis
• Non-Alcoholic Fatty Liver Disease
• Nephrology and Hepatology
• Liver Function Tests
• Milk Thistle
• Kava
• Valerian
• Comfrey
• Dandelion
• N-Acetylcysteine
• Glutathione
• Toxins

Safety and disclaimer. This page is educational and is not medical advice or a diagnostic tool. Germander (Teucrium species) is hepatotoxic in any form. American skullcap (Scutellaria lateriflora, aerial parts) has no established hepatotoxic constituent, but skullcap-labelled products have been associated with liver injury and germander substitution is the leading explanation — which makes verified product identity the single most important safety step, not an optional refinement. Chinese skullcap root (Scutellaria baicalensis) carries its own separate liver-injury signal. The research raises a concern for either species in people with liver disease, a history of drug- or herb-induced liver injury, or heavy alcohol use; there is insufficient safety data in pregnancy and breastfeeding; sedatives, alcohol and surgery are further concerns; and liver-toxic prescription medicines add to the load on the liver. Unusual fatigue, nausea, right-upper-abdominal pain, dark urine, pale stools, itching, or yellowing of the skin or eyes are signs of liver injury that hospitals treat as urgent; in the reported germander cases recovery followed stopping the product, and the actual product is what allows it to be checked.

Back to Table of Contents

Featured Videos